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To evaluate the in vitro effects of the combination of ceftazidime and avibactam on the MICs of both compounds, checkerboard
assays were performed for 81 clinical strains, including 55 Enterobacteriaceae strains (32 Klebsiella pneumoniae, 19 Escherichia
coli, 1 Citrobacter freundii, and 3 Enterobacter cloacae) and 26 strains of Pseudomonas aeruginosa, all with known resistance
mechanisms such as extended-spectrum -lactamases (ESBLs) and carbapenemases, phenotypically or molecularly determined.
Phenotypically ceftazidime-resistant strains (n 69) were analyzed in more detail. For the Enterobacteriaceae strains, a concen-
tration-dependent effect of avibactam was found for most strains with a maximum effect of avibactam at a concentration of 4
mg/liter, which decreased all ceftazidimeMICs to<4 mg/liter. Avibactam alone also showed antibacterial activity (the MIC50
andMIC90 being 8 and 16 mg/liter, respectively). For the ceftazidime-resistant P. aeruginosa strains, considerable inhibition of
-lactamases by avibactam was acquired at a concentration of 4 mg/liter, which decreased all ceftazidimeMICs except one to<8
mg/liter (the CLSI and EUCAST susceptible breakpoint). Increasing the concentration of avibactam further decreased theMICs,
resulting in a maximum effect for most strains at 8 to 16 mg/liter. In summary, for most strains, the tested addition of avibactam
of 4 mg/liter restored the antibacterial activity of ceftazidime to a level comparable to that of wild-type strains, indicating full
inhibition, and strains became susceptible according to the EUCAST and CLSI criteria. Based on these in vitro data, avibactam is
a promising inhibitor of different -lactamases, including ESBLs and carbapenemases.
Antibiotic resistance is a worldwide problem. Until the pastdecade, the development of new classes of antibiotics was an
important weapon against development of resistance. However,
strains that carry extended-spectrum -lactamases and/or car-
bapenemases have emerged (1, 2). In some countries, the resis-
tance levels to these drugs are now 50% (3). One approach for
overcoming this mechanism of resistance is by inhibition of these
enzymes. This approach has been taken in the past against -lac-
tamase-carrying strains using drug combinations consisting of a
-lactam agent and a -lactamase inhibitor (4–11), such as
piperacillin-tazobactam and amoxicillin-clavulanic acid. These
have been and still are among the most successful antimicrobials
available.
Among several new -lactamase inhibitors and combinations
with -lactams that are currently being developed is avibactam (12,
13). This compound is active against Ambler class A extended-
spectrum -lactamases (ESBLs) (e.g., TEM, SHV, and CTX-M
types), KPC class A enzymes, class C (AmpC), and some class D
enzymes. Studies in vitro (14–24) have shown that the MICs of
ceftazidime for many resistant strains were markedly reduced in
the presence of avibactam and thereby became susceptible.
An important step in the development of a combination-lac-
tam–-lactamase inhibitor is to determine the concentration-ef-
fect relationship and the concentration at which maximal in vitro
inhibition is achieved. These relationships can subsequently be
used to determine the optimal conditions to correlate the in vitro
testing with the efficacy of the combination. Therefore, we em-
ployed a checkerboard assay (25) to evaluate the in vitro effects of
ceftazidime combined with avibactam over a range of concentra-
tions for a selection of clinical Gram-negative isolates, including
Enterobacteriaceae and Pseudomonas aeruginosa.
MATERIALS AND METHODS
Antibacterials. Ceftazidime (lot no. G263848; potency 77.0%) and
avibactam (lot no. AFCH005151; potency 91.7%) were provided by
AstraZeneca Pharmaceuticals LP (Waltham, MA, USA). The drugs were
reconstituted in sterile water to a stock solution of 5,120 mg/liter, and
further solutions were prepared in Mueller-Hinton broth (Difco;
Brunschwig Chemie, Amsterdam, The Netherlands).
Bacterial strains. Originally, 81 ceftazidime-resistant strains were ob-
tained, all from clinical samples from a wide variety of infections, one
strain per patient. The strains were chosen because they represent differ-
ent -lactamase-mediated mechanisms of resistance and thus did not
quantitatively represent the presence of such resistance mechanisms in the
general population, i.e., unselected clinical isolates. Of the isolates, 69
were retained after susceptibility testing, because they were phenotypi-
cally ceftazidime resistant or intermediate according to the MIC and
EUCAST interpretive criteria. A list describing the strains is provided in
Table 1. Included in this selection were 51 Enterobacteriaceae (18 Esche-
richia coli, 29 Klebsiella pneumoniae, 3 Enterobacter cloacae, and 1 Citro-
bacter freundii) and 18 P. aeruginosa isolates.
Susceptibility testing. The MICs of ceftazidime and avibactam were
determined by microdilution according to the ISO guidelines (26). The
drugs were reconstituted in sterile water to a stock solution of 5,120 mg/
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liter, and further solutions were prepared in Mueller-Hinton broth
(Difco; Brunschwig Chemie). Checkerboards were set up with 2-fold di-
lutions of ceftazidime (0.032 to 256 mg/liter) and avibactam (0.016 to 16
mg/liter). Freshly prepared trays were stored at 80°C until use. Every
tray contained a negative control and a growth control. Each set of MIC
determinations included three control strains: E. coli ATCC 25922, P.
aeruginosa ATCC 27853, and K. pneumoniae ATCC 700603. Three to 5l
of 1.5 107 CFU/ml bacterial suspension was added in each well with an
inoculator (INOC 2001; Bitel Mechatronics B.V., INOC B.V., Zevenber-
gen, The Netherlands). Plates were read after 18 to 20 h of incubation at
35°C in a closed plastic box using a mirrored surface. The MIC was re-
corded as the lowest concentration of the agent that completely inhibited
visible growth. All experiments were performed in duplicate.
Analysis. The susceptibility of the combination was interpreted fol-
lowing the EUCAST criteria for ceftazidime (27) (Enterobacteriaceae: sus-
ceptible, 1 mg/liter; resistant, 4 mg/liter; P. aeruginosa: susceptible,
8 mg/liter; resistant, 8 mg/liter). Results are expressed as the MIC50
and MIC90 of ceftazidime and the concentrations of avibactam required to
reduce the MIC of ceftazidime (Prism, version 6, 2013; GraphPad Soft-
ware, San Diego, CA).
RESULTS
Avibactam alone did not have a significant inhibitory effect on P.
aeruginosa nor on C. freundii isolates, whereas it did have an in-
hibitory effect on other Enterobacteriaceae strains, with a MIC of 8
mg/liter (the majority of E. coli and K. pneumoniae strains) or 16
mg/liter (1 of the 3 E. cloacae strains) for avibactam in the absence
of ceftazidime (data not shown).
Figures 1 and 2 show the effects of increasing concentrations of
avibactam on the MIC of ceftazidime as cumulative inhibition for
P. aeruginosa isolates and Enterobacteriaceae strains, respectively.
The cumulative inhibition plots are shifted to the left for increas-
ing concentrations of avibactam, indicating a clear effect: the
higher the concentration of avibactam present, the lower the re-
sulting MIC for ceftazidime.
Table 2 shows the MIC50 and MIC90 values of ceftazidime at
various concentrations of avibactam and provides an indication of
the concentration of avibactam required to reduce the MICs for
ceftazidime forEnterobacteriaceae andP. aeruginosa strains. A rea-
sonable shift of MICs was already attained with the addition of
only 0.016 mg/liter avibactam. The impact of avibactam on the
Enterobacteriaceae strains was more pronounced than for the P.
aeruginosa isolates. A maximum concentration of avibactam of 4
mg/liter resulted in susceptibility for Enterobacteriaceae, whereas
for P. aeruginosa 8 to 16 mg/liter avibactam was required to reach
susceptible levels for all strains.
Figure 3 shows the maximum decrease in ceftazidime MICs in
number of 2-fold dilutions. Addition of avibactam to ceftazidime
reduced the MIC of ceftazidime up to 7 to 9 2-fold dilutions for the
majority of the Enterobacteriaceae strains, and the maximum ef-
fect was reached at an avibactam concentration of 4 mg/liter. For
the P. aeruginosa strains, the maximum effect was less pro-
nounced: 5 to 6 doubling dilutions and higher concentrations of
avibactam, up to 8 to 16 mg/liter, were required. OneP. aeruginosa
TABLE 1 Resistance specifications of the 69 ceftazidime-resistant
clinical isolates used in the checkerboard assay
No. of
strains Genus and species Resistance specificationsa
18 Pseudomonas aeruginosa Ceftazidime resistant, carbapenem
resistant, AmpCcon, AmpCind,
KPC-2
29 Klebsiella pneumoniae OmpK35, OmpK36, KPC, KPC-2
and -3, CTX-M-15, gr. 9, 39,
TEM-1 and -84, SHV-1, -2, -5,
-11, -12, and -33, OXA-1, -2, and
-48, LEN, GES-1, ESBL, possible
carbapenemases, AmpC
18 Escherichia coli CTX-M-1, -2, -3, and -15, TEM-1
and -84, SHV-1 and -12, OXA-1,
ESBL
3 Enterobacter cloacae CTX-M-9, TEM-1, SHV-12, OXA-1
1 Citrobacter freundii KPC-2
a AmpCcon, AmpC derepressed; AmpCind, AmpC inducible.
FIG 1 Cumulative % inhibition of 18 P. aeruginosa isolates by ceftazidime for increasing concentrations (symbols below the figure, mg/liter) of avibactam. The
% inhibition of growth of P. aeruginosa is presented on the y axis with the MIC for ceftazidime on the x axis as related to the added concentrations of avibactam
in differently colored lines.
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isolate did not show any change in the MIC of ceftazidime in
combination with the highest concentration of avibactam added.
Table 3 displays target MICs of ceftazidime for Enterobacteria-
ceae and P. aeruginosa isolates and the required concentrations of
avibactam expressed as the 50th and 90th percentiles. The median
and 90th percentile concentrations of avibactam required to re-
duce the MIC of ceftazidime to 4 mg/liter were 4 and16 mg/liter
for P. aeruginosa strains, 0.016 and 0.063 mg/liter for E. coli
strains, and 0.250 and 1 mg/liter for K. pneumoniae strains respec-
tively. The median and 90th percentile concentrations of avibac-
tam required to reduce the MIC of ceftazidime to 1 mg/liter were
32 and64 mg/liter (i.e., the measurable MIC90 was not attained)
forP. aeruginosa strains, 0.031 and 2 mg/liter forE. coli strains, and
2 and 8 mg/liter for K. pneumoniae strains, respectively.
At an avibactam concentration of 1 mg/liter, the MIC50 of cef-
tazidime against the isolates of P. aeruginosa was at or below the
ceftazidime resistance breakpoint of 8 mg/liter (as shown in Table
2). The MIC90, however, was much higher (32 mg/liter). At a
concentration of avibactam of 4 mg/liter (as currently used for in
vitro broth dilution susceptibility testing) (28), the MIC90 for the
ceftazidime-avibactam combination was 16 mg/liter, one dilution
higher than both the EUCAST and CLSI breakpoints of ceftazi-
dime for P. aeruginosa. The median and 90th percentile concen-
trations of avibactam for P. aeruginosa isolates for three different
MICs of the ceftazidime-avibactam combination indicate that
avibactam is particularly effective with P. aeruginosa at concentra-
tions of 8 to 16 mg/liter (Table 3).
Likewise the MIC50 and MIC90 of ceftazidime-avibactam for
Enterobacteriaceae strains decreased with increasing concentra-
tions of avibactam. Of note, avibactam showed some moderate
FIG 2 Cumulative % inhibition of 51 Enterobacteriaceae isolates by ceftazidime for increasing concentrations (symbols below the figure, mg/liter) avibactam.
The % inhibition of growth of Enterobacteriaceae is presented on the y axis with the MIC for ceftazidime on the x axis as related to the added concentration of
avibactam in differently colored lines.
TABLE 2 MIC50 and MIC90 values of ceftazidime at increasing concentrations of avibactam
Avibactam concn
(mg/liter)
P. aeruginosa (n 18)
All Enterobacteriaceae
(n 51) E. coli (n 18) K. pneumoniae (n 29)
MIC50
(mg/liter)
MIC90
(mg/liter)
MIC50
(mg/liter)
MIC90
(mg/liter)
MIC50
(mg/liter)
MIC90
(mg/liter)
MIC50
(mg/liter)
MIC90
(mg/liter)
0 32 128 32 512 32 64 128 512
0.016 32 128 8 128 2 16 32 128
0.031 32 128 4 64 1 8 16 128
0.063 32 128 2 16 1 2 8 128
0.125 32 128 2 16 1 2 8 64
0.25 32 128 2 8 1 2 4 64
0.5 16 64 2 8 0.5 2 2 8
1 8 32 1 4 0.5 1 1 4
2 4 16 1 2 0.5 1 1 2
4 4 16 0.5 1 0.25 0.5 0.5 2
8 2 8 0.031 0.25 0.031 0.063 0.031 0.25
16 2 8 0.031 0.031 0.031 0.031 0.031 0.031
32 1 4
64 1 4
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antibacterial activity without ceftazidime (range, 8 to 16 mg/
liter; MIC50 and MIC90 of avibactam, respectively, 8 and 16 mg/
liter). This resulted in a very low MIC50 and MIC90 of the ceftazi-
dime-avibactam combination for Enterobacteriaceae strains. For
all the Enterobacteriaceae strains tested, at a concentration of 1
mg/liter of avibactam, the MIC90 of the combination was at or
below the ceftazidime-susceptible breakpoint of 4 mg/liter. The
effect of avibactam was species dependent, the MICs of the com-
bination against E. coli isolates being reduced to a MIC90 of 2
mg/liter when the concentration of avibactam was 0.063 mg/liter,
whereas 1 mg/liter avibactam was required to bring the MIC90 of
the combination against K. pneumoniae isolates to 4 mg/liter.
DISCUSSION
In this study, it was shown that the addition of avibactam renders
ESBL-producing strains susceptible to ceftazidime, but that the
concentration of avibactam required is species and strain depen-
dent. Although the efficacy of the combination of avibactam and
ceftazidime in vitro was described in earlier studies for some con-
centrations of avibactam (14, 16, 18, 21, 23), we here present the
results of complete checkerboard experiments.
It should be noted that the isolates of Enterobacteriaceae and P.
aeruginosa studied in the present work were selected for further
investigation due to ceftazidime resistance, i.e., the ceftazidime or
ceftazidime-avibactam MIC distributions of the isolates studied
are not representative of the normal MIC distribution observed in
a routine clinical laboratory. The median and 90th percentile ta-
bles and the cumulative frequency plots are ways of displaying the
collected properties of the sample of isolates chosen. They are not
in any way estimates of the MIC distribution statistics of any cur-
rent population of clinical isolates. The value of this collection is as
a challenge set of bacteria that can be used to study the concentra-
tion-effect profile of avibactam when combined with ceftazidime
against -lactamase-producing isolates. These baseline results
were important for ensuing pharmacokinetic/pharmacodynamic
(PK/PD) studies (e.g., reference 29).
The results of the checkerboard experiments were analyzed in
different ways. First, the maximum effective concentration of
avibactam was determined for the different microorganisms and
species. From these data, it can be concluded that the activity of
avibactam in combination with ceftazidime is more pronounced
for Enterobacteriaceae than for P. aeruginosa strains. The possible
explanations include the existence of more and different resis-
tance mechanisms present in Pseudomonas species compared to
the Enterobacteriaceae, such as resistance due to changes in porins
or efflux pumps (30, 31).
Except for one strain of P. aeruginosa, avibactam restored the
antibacterial activity of ceftazidime to a level comparable to that of
wild-type strains (even though a concentration of 32 mg/liter
avibactam was required to reach this for strain 11), which renders
them susceptible according to both the CLSI and the EUCAST
criteria. This is consistent with what was observed for a collection
of unselected clinical isolates of P. aeruginosa where the addition
of avibactam at 4 mg/liter restored the antibacterial activity of
ceftazidime (32) and reverted the frequency distribution of the
MICs of ceftazidime to one resembling the EUCAST “wild-type”
distribution (33).
Second, the optimum inhibitory combinations of ceftazidime
and avibactam in vitro were derived from the data. Ideally, the
concentration of avibactam to use is such that the majority of
strains are inhibited by ceftazidime-avibactam and, on the other
hand, that distinguishes between strains that harbor enzymes that
are susceptible or resistant to avibactam inhibition at the putative
breakpoint level of ceftazidime-avibactam. This is not necessarily
the same as the breakpoint for ceftazidime owing to consider-
ations of dosing, human population pharmacokinetics, PK/PD
indices and magnitudes, MIC frequency distributions in surveil-
FIG 3 Distribution of the maximum effect of ceftazidime-avibactam combinations over the tested concentration range expressed as a 2-fold dilution of the MIC
decrease of ceftazidime. The maximum MIC-lowering effect of the addition of avibactam to ceftazidime (compared to the MIC of ceftazidime alone) for % strains
of both Enterobacteriaceae and P. aeruginosa is presented on a 2-log transformed x axis.
TABLE 3 Concentration of avibactam required to reach a given MIC of
ceftazidime for the median and 90th percentile of strains
Ceftazidime
target MIC
(mg/liter)
MICs of avibactam (50th/90th percentiles [mg/liter]) for:
P. aeruginosa
(n 18)
Enterobacteriaceae
all (n 51)
E. coli
(n 18)
K. pneumoniae
(n 29)
1 32/64 1/4 0.031/2 2/8
4 4/16 0.063/1 0.016/0.063 0.250/1
8 1/8 0.031/0.25 0.016/0.031 0.125/0.5
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lance studies, activity against key multidrug-resistant strains, and
clinical data.
At an avibactam concentration of 1 mg/liter, the MIC50 of cef-
tazidime against the isolates of P. aeruginosa was at or below the
ceftazidime resistance breakpoint of 8 mg/liter (note that this
breakpoint is associated with the 2-g, every 8 h [q8h] dose of
ceftazidime, whereas the ceftazidime breakpoint for Enterobacte-
riaceae of 4 mg/liter was set based on the 1-g, q8h dose [EUCAST
ceftazidime breakpoint rationale document (34)]). The MIC90 of
ceftazidime at the avibactam concentration of 1 mg/liter was
much higher (32 mg/liter).
In the presence of a fixed amount of 4 mg/liter avibactam, 92%
of all of the bacterial strains tested displayed a MIC to the combi-
nation of4 mg/liter. However, a number of strains of P. aerugi-
nosa required significantly higher concentrations of avibactam in
the range of 8 to 32 mg/liter (in vitro) to achieve the ceftazidime-
susceptible breakpoint. The current dosing (2,000 mg ceftazidime
and 500 mg avibactam q8h, 2-h infusion per dose [35]) will most
likely not result in concentrations high enough or long enough to
inhibit these specific strains in vivo.
It should be noted that the P. aeruginosa isolates selected for
this study represented isolates from the high end of the MIC dis-
tribution of current clinical isolates (14, 32) in order to identify
strains suitable for PK/PD analyses in murine infection studies
(e.g., see reference 29). The concentration of avibactam used in
susceptibility testing cannot be related directly to the fluctuating
avibactam concentrations in vivo. Rather, the in vitro test is de-
signed so that a constant concentration of avibactam inhibits
-lactamases as much as is practicable in order to reveal the in-
trinsic susceptibility to ceftazidime which is diluted in 2-fold in-
crements, read as the “MIC.” In vivo, the question becomes what
PK time course of concentrations of avibactam will inhibit -lac-
tamases and support the underlying intrinsic PK/PD of avibac-
tam? (29, 36, 37). That is outside the scope of the present work, but
suffice it to say that it need not be related exactly to the 4 mg/liter
avibactam adopted as the fixed susceptibility test concentration
(28).
The resulting data provide a basis for determining the optimal
avibactam concentration in routine susceptibility testing in mi-
crodilution assays. The data indicate that a concentration of
avibactam of 4 mg/liter will give the best result while ensuring that
the concentration remains below the point at which avibactam
begins to show some antibacterial activity alone in the case of
Enterobacteriaceae strains (Table 1), which might potentially yield
in vitro test results of false susceptibility (i.e., very major errors).
This is consistent with the currently adopted standard method set
by the CLSI (28, 38).
The MIC-lowering effect was far more pronounced for the
Enterobacteriaceae strains. For most strains, 1 mg/liter of avibac-
tam was enough to reach the maximum -lactamase inhibition,
and the -lactamases of virtually all strains were inhibited at 4
mg/liter. The -lactamases expressed in E. coli isolates in particu-
lar were very susceptible to avibactam with concentrations as low
as 0.063 mg/liter reinstating susceptibility to ceftazidime, whereas
for the K. pneumoniae and other Enterobacteriaceae isolates, 1 mg/
liter was necessary. The stepwise increase in ceftazidime suscepti-
bility with increasing avibactam concentration leads to the hy-
pothesis that multiple steps interact in the restoration of
ceftazidime activity by avibactam and that each step contributes to
a different extent in different strains. For K. pneumoniae, avibac-
tam at 4 mg/liter brought MIC values of ceftazidime against all of
the challenge isolates in this selected sample to4 mg/liter (Table
1) and of 90% to 2 mg/liter (Table 2). In the attempt to relate
this observation to the clinical standards of the MIC interpretive
criteria, it is relevant to note that the PK/PD target attainment
based cutoff MIC for the 1-g, q8h dose of ceftazidime is 4 mg/liter
(28, 34, 38). The current EUCAST ceftazidime-susceptible break-
point of 1 mg/liter was lowered from the PK/PD cutoff of 4
mg/liter in order to avoid categorization of ESBL producers inhib-
ited by 2 or 4 mg/liter as susceptible (34). However, the combina-
tion of ceftazidime with avibactam is designed to overcome the
hydrolysis by ESBLs, and, thus, the PK/PD target attainment based
on the 1-g, q8h ceftazidime dose might support a susceptible
breakpoint of4 mg/liter. Indeed, this is currently the CLSI MIC-
based interpretive criterion of ceftazidime susceptible (28). In the
case of ceftazidime-avibactam, the dose is 2 g ceftazidime (plus 0.5
g avibactam), q8h, and the infusion time is 120 min rather than the
standard 30 min used for ceftazidime, so the PK/PD cutoff is pro-
portionately higher (35, 39). It should be noted that the PK/PD
cutoff for the 2-g, 8-h dose of ceftazidime supports the clinical
susceptible interpretive criterion of 8 mg/liter applied to P.
aeruginosa by both the CLSI (28, 38) and the EUCAST (34). In
summary, when one is attempting to relate the ceftazidime-
avibactam MIC values against the challenge isolates reported here
to any putative susceptibility interpretive criterion, the appropri-
ate value to use ultimately will be the PK/PD cutoff of the q8h
120-min infusion dose of 2 g ceftazidime combined with 0.5 g
avibactam, the definitive analysis of which has yet to be per-
formed, because phase 3 clinical trials are in progress (but see
references 35 and 39 for pre-phase 3 models and analyses).
The MICs for ceftazidime were also lowered for phenotypically
ceftazidime-susceptible strains (data not shown). This can possi-
bly be explained by a baseline level of-lactamase production that
elevates the baseline MIC of ceftazidime, in which case avibactam
potentially removes that baseline activity. Hitherto, the mecha-
nism of synergy between avibactam and ceftazidime had not been
investigated.
Since it might be possible that there was a specific trend in the
results, depending on the selected microorganisms or on the re-
sistance mechanism these microorganisms possessed, we specifi-
cally looked at whether this was the case. No clear differences
related to the type of ESBL present or to the presence of one or
more ESBLs were visible, although there are biochemical kinetic
differences in the inhibition of different-lactamases in vitro (12).
Another factor that might affect the ability of avibactam to lower
the MICs of ceftazidime is that the number of copies per cell may
differ, requiring more or less avibactam.
Similar to earlier observations, we did not find any intrinsic
antipseudomonal activity of avibactam alone (MICs of16 or 64
mg/liter) (18, 24), and the primary use of avibactam is the inhibi-
tion of -lactamases, including multidrug-resistant (MDR)
strains. Ceftazidime activity was restored from 40% to 96% in 25
MDR P. aeruginosa isolates (18), where MDR was defined as re-
sistance to at least one antimicrobial agent from three or more
different classes. The molecular resistance mechanisms were not
mentioned in this study. Similarly, Levasseur et al. (14) showed an
increase in the ceftazidime susceptibility from 65% to 94% with
the addition of 4 mg/liter avibactam in 126 consecutive clinical P.
aeruginosa isolates. The activity against AmpC-mediated resis-
tance was shown by Mushtaq and colleagues when they demon-
Berkhout et al.
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strated that avibactam reversed the AmpC-mediated ceftazidime
resistance in P. aeruginosa isolates, by reducing the MICs for fully
derepressed mutants and isolates to8 mg/liter (21). The 6 Pseu-
domonas isolates carrying AmpC in the present study also turned
susceptible with addition of avibactam.
For Enterobacteriaceae, avibactam has shown significant activ-
ity against class A, C, and some D-lactamases but not to metallo-
-lactamases (24). These include KPC-producing strains (23),
strains producing the OXA-48 enzyme (16, 20, 40, 41), and AmpC
-lactamases (19). In the present study, we likewise found activity
against each of these resistance mechanisms.
The studies discussed above and our own study indicate that
avibactam is a promising inhibitor of different -lactamases, in-
cluding ESBLs and KPC-type carbapenemases, and might be an
alternative treatment option for infections caused by ESBL-har-
boring strains. The checkerboard approach that we took indicates
that there is a concentration-dependent effect of avibactam.
Whereas the 4 mg/liter used in susceptibility testing brought the
ceftazidime MICs against the Enterobacteriaceae strains to4 mg/
liter (the CLSI breakpoint and the EUCAST PK/PD cutoff for the
1-g, q8h dose) and against the majority of theP. aeruginosa isolates
in the present study to8 mg/liter (the CLSI and EUCAST break-
points), the concentration dependence also raises the hypothesis
that higher exposures of avibactam, if proven safe, might ulti-
mately lead to more isolates being susceptible in vivo, particularly
among multidrug-resistant P. aeruginosa strains.
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